Ascletis Presented Phase Iii Study Results of First-in-Class Fasn Inhibitor Denifanstat (Asc40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (Eadv) Congress 2025

THOMSON REUTERS
Sep 18

Ascletis Presented Phase Iii Study Results of First-in-Class Fasn Inhibitor Denifanstat (Asc40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (Eadv) Congress 2025

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10